摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-amino-4-imino-2-methyl-2H-4,5-dihydropyrazolo[3,4-d]pyrimidine | 728042-77-1

中文名称
——
中文别名
——
英文名称
5-amino-4-imino-2-methyl-2H-4,5-dihydropyrazolo[3,4-d]pyrimidine
英文别名
4-imino-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-5(4H)-amine;4-imino-2-methyl-2,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-amine;5-amino-4-imino-2-methylpyrazolo[3,4-d]pyrimidine;4-Imino-2-methylpyrazolo[3,4-d]pyrimidin-5-amine
5-amino-4-imino-2-methyl-2H-4,5-dihydropyrazolo[3,4-d]pyrimidine化学式
CAS
728042-77-1
化学式
C6H8N6
mdl
——
分子量
164.17
InChiKey
MDUYRDKNKPZCER-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    364.8±34.0 °C(Predicted)
  • 密度:
    1.71±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    83.3
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Does the combination of optimal substitutions at the C2-, N5- and N8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?
    摘要:
    In an attempt to study the optimal combination of a phenyl ring at the C-2-position and different substituents at the N-5- and N-8-positions towards the selective modulation of human A(3) adenosine receptors (hA(3)AR), we synthesized a new series of 2-para-(un)substituted-phenyl-pyrazolo-triazolo-pyrimidines bearing either a methyl or phenylethyl at N-8 and chains of variable length at N-5. Through biological evaluation, it was found that the majority of the compounds had good affinities towards the hA(3)AR in the low nanomolar range. Compound 16 possessed the best hA(3)AR affinity and selectivity profile (K(i)hA(3) = 1.33 nM; hA(1)/hA(3) = 4880; hA(2A)/hA(3) = 1100) in the present series of2-(substituted)phenylpyrazolo-triazolo-pyrimidine derivatives. In addition to pharmacological characterization, a molecular modeling investigation on these compounds further elucidated the effect of different substituents at the pyrazolo-triazolo-pyrimidine scaffold on affinity and selectivity to hA3AR. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.08.026
  • 作为产物:
    参考文献:
    名称:
    人类A3腺苷受体的有机钌拮抗剂
    摘要:
    人A 3腺苷受体(hA 3 AR)是膜结合的G蛋白偶联受体,与许多严重的病理状况(包括癌症)有关,在其中它可能成为潜在的治疗靶标。为了推导基于吡唑并三唑并嘧啶(PTP)的A 3 AR拮抗剂的构效关系,我们通过用有机钌片段代替三唑并开发了新型的有机金属抑制剂。目的是通过设计将结构多样性引入PTP支架中,以调节其对靶受体的结合功效。这些新型的有机钌拮抗剂显示出良好的水生稳定性和对hA 3的中等结合亲和力受体在低微摩尔范围内。讨论了通过模板驱动的方法组装这些复合物,并在金属中心进行选择性配体置换以控制其空间和受体结合特性的方法。
    DOI:
    10.1002/chem.201203291
点击查看最新优质反应信息

文献信息

  • Organoruthenium Antagonists of Human A<sub>3</sub>Adenosine Receptors
    作者:Priyankar Paira、Mun Juinn Chow、Gopalakrishnan Venkatesan、Vamsi Krishna Kosaraju、Siew Lee Cheong、Karl-Norbert Klotz、Wee Han Ang、Giorgia Pastorin
    DOI:10.1002/chem.201203291
    日期:2013.6.17
    triazolo moiety with an organoruthenium fragment. The objective was to introduce by design structural diversity into the PTP scaffold in order to tune their binding efficacy toward the target receptor. These novel organoruthenium antagonists displayed good aquatic stability and moderate binding affinity toward the hA3 receptor in the low micromolar range. The assembly of these complexes through a template‐driven
    人A 3腺苷受体(hA 3 AR)是膜结合的G蛋白偶联受体,与许多严重的病理状况(包括癌症)有关,在其中它可能成为潜在的治疗靶标。为了推导基于吡唑并三唑并嘧啶(PTP)的A 3 AR拮抗剂的构效关系,我们通过用有机钌片段代替三唑并开发了新型的有机金属抑制剂。目的是通过设计将结构多样性引入PTP支架中,以调节其对靶受体的结合功效。这些新型的有机钌拮抗剂显示出良好的水生稳定性和对hA 3的中等结合亲和力受体在低微摩尔范围内。讨论了通过模板驱动的方法组装这些复合物,并在金属中心进行选择性配体置换以控制其空间和受体结合特性的方法。
  • A new synthesis of 2,8-disubstituted pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines
    作者:Anton V. Dolzhenko、Giorgia Pastorin、Anna V. Dolzhenko、Wai Keung Chui
    DOI:10.1016/j.tetlet.2009.07.113
    日期:2009.10
    5-c]pyrimidines, which are key intermediates in the preparation of adenosine receptor antagonists, is developed. The method allows introduction of a variety of aryl substituents at position 2 of the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine system via cyclocondensation of 5-amino-4-iminopyrazolo[3,4-d]pyrimidine with benzaldehydes accompanied with oxidation by iodobenzene diacetate. Some unexpected
    开发了实用的吡唑并[4,3- e ] [1,2,4]三唑并[1,5- c ]嘧啶的合成方法,它们是制备腺苷受体拮抗剂的关键中间体。该方法允许通过5-氨基-4-亚氨基吡唑并环缩合在吡唑并[4,3- e ] [1,2,4]三唑并[1,5- c ]嘧啶体系的2位引入各种芳基取代基。[3,4- d ]嘧啶与苯甲醛并伴随有碘代二苯乙酸酯的氧化。观察到一些意想不到的反应,并使用NMR光谱和X射线晶体学证实了产物的结构。
  • Synthesis of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines and related heterocycles
    作者:Pier Giovanni Baraldi、Hussein El-Kashef、Abdel-Rahman Farghaly、Patrice Vanelle、Francesca Fruttarolo
    DOI:10.1016/j.tet.2004.04.010
    日期:2004.5
    The reaction between 5-amino-4-imino-1(2)-substituted-1(2)H-4,5-dihydropyrazolo[3,4-d]pyrimidines and several commercially available reactants afforded new heterocycles with a conserved pyrazolo[3,4-d]pyrimidine nucleus. The key intermediates employed proved to be suitable compounds by virtue of their two vicinal amino and imino groups that were used to obtain five, six and seven-membered rings.
    5-氨基-4-亚氨基-1(2)-取代的-1(2)H -4,5-二氢吡唑并[ 3,4- d ]嘧啶与几种市售反应物之间的反应提供了具有保守的吡唑并[1]的新杂环。 3,4- d ]嘧啶核。由于其两个邻位氨基和亚氨基被用于获得五元,六元和七元环,因此所证明的关键中间体是合适的化合物。
  • Does the combination of optimal substitutions at the C2-, N5- and N8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?
    作者:Siew Lee Cheong、Anton V. Dolzhenko、Silvia Paoletta、Evelyn Pei Rong Lee、Sonja Kachler、Stephanie Federico、Karl-Norbert Klotz、Anna V. Dolzhenko、Giampiero Spalluto、Stefano Moro、Giorgia Pastorin
    DOI:10.1016/j.bmc.2011.08.026
    日期:2011.10
    In an attempt to study the optimal combination of a phenyl ring at the C-2-position and different substituents at the N-5- and N-8-positions towards the selective modulation of human A(3) adenosine receptors (hA(3)AR), we synthesized a new series of 2-para-(un)substituted-phenyl-pyrazolo-triazolo-pyrimidines bearing either a methyl or phenylethyl at N-8 and chains of variable length at N-5. Through biological evaluation, it was found that the majority of the compounds had good affinities towards the hA(3)AR in the low nanomolar range. Compound 16 possessed the best hA(3)AR affinity and selectivity profile (K(i)hA(3) = 1.33 nM; hA(1)/hA(3) = 4880; hA(2A)/hA(3) = 1100) in the present series of2-(substituted)phenylpyrazolo-triazolo-pyrimidine derivatives. In addition to pharmacological characterization, a molecular modeling investigation on these compounds further elucidated the effect of different substituents at the pyrazolo-triazolo-pyrimidine scaffold on affinity and selectivity to hA3AR. (C) 2011 Elsevier Ltd. All rights reserved.
  • Unprecedented synthesis of a 14-membered hexaazamacrocycle
    作者:Anastasia A Fesenko、Anatoly D Shutalev
    DOI:10.3762/bjoc.19.126
    日期:——
    4'-l][1,2,4,8,9,11]hexaazacyclotetradecine-4,12-diamine, by the reaction with excess hydrazine under various conditions was studied in detail. The reaction proceeded through the initial formation of 4-imino-2-methyl-2,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-amine followed by dimerization to give the final macrocycle. A convenient synthesis of the latter starting from 4-imino-2-methyl-2,4-dihydro-5H-pyrazolo[3
    摘要 3-[(乙氧基亚甲基)氨基]-1-甲基-1H-吡唑-4-甲腈转化为14元大环2,10-二甲基-2,8,10,16-四氢二吡唑[3,4 -e : 3',4'- l ][1,2,4,8,9,11]六氮杂环十四胺-4,12-二胺在各种条件下与过量肼反应进行了详细研究。该反应首先形成4-亚氨基-2-甲基-2,4-二氢-5H-吡唑并[3,4- d ]嘧啶-5-胺,然后二聚得到最终的大环。开发了一种以 4-亚氨基-2-甲基-2,4-二氢-5 H-吡唑并[3,4- d ]嘧啶-5-胺为原料的便捷合成方法。讨论了大环自组装的合理途径。概述了所获得的大环的结构和反应性的一些特征。 贝尔斯坦 J. 组织。化学。 2023, 19, 1728–1740。doi:10.3762/bjoc.19.126
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺